Monitor for the filing of the resale registration statement with the SEC and upcoming clinical data readouts for KRRO-121 and the AATD program, which could serve as key catalysts. Be aware of potential near-term dilution from warrant overhang despite extended runway.
Price Chart
Executive Summary
Korro Bio (KRRO) announced a $85 million PIPE financing led by Venrock Healthcare Capital Partners, with participation from several new and existing investors. The proceeds, combined with $85.2 million in existing cash, are expected to extend the company's cash runway into the second half of 2028, funding clinical development of its RNA editing programs including KRRO-121 and its GalNAc-conjugated AATD therapy.
Key Financial Metrics
Key Facts
- Korro Bio raised approximately $85 million in a PIPE financing.
- The financing includes 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for 3,148,836 shares at $11.109 per warrant, exercisable at $0.001 per share.
- Proceeds, combined with $85.2 million in cash as of December 31, 2025, will extend cash runway into H2 2028.
- Funds will support clinical milestones for KRRO-121 (urea cycle disorders) and GalNAc-conjugated AATD program, as well as a longevity/liver health program targeting AMPKγ1.
- Citigroup, Cantor, Oppenheimer & Co., and William Blair acted as placement agents.
- A registration rights agreement requires Korro to file a resale registration statement with the SEC.
Financial Impact
Gross proceeds of $85 million from a PIPE financing; combined with $85.2 million in existing cash, significantly extends financial runway.
Risk Factors
- Pre-funded warrants may lead to future dilution when exercised, despite minimal exercise price.
- Forward-looking statements about cash runway and clinical milestones are subject to risks including trial delays, regulatory hurdles, and financing conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Insider Buy | $12.46 | awaiting T+1 | — | $12.02 (−3.53%) |
Oct 22, 2026 4d ago | 8-K | $12.05 $11.98 | ▼ −0.58% | ▼ −0.06% | $12.02 (−0.25%) |
Oct 16, 2026 10d ago | Press Release | $8.91 $9.44 | ▲ +5.95% | ▲ +5.61% | $12.02 (+34.90%) |
Oct 5, 2026 21d ago | 8-K | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Oct 5, 2026 21d ago | Press Release | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Sep 15, 2026 5w ago | Insider Cluster | $13.83 $11.80 | ▼ −14.68% | ▼ −15.81% | $12.02 (−13.09%) |
Aug 13, 2026 10w ago | Insider Cluster | $13.29 $13.28 | ▼ −0.08% | ▲ +0.12% | $12.02 (−9.56%) |
Aug 6, 2026 11w ago | 8-K | $12.12 $13.25 | ▲ +9.32% | ▲ +8.71% | $12.02 (−0.83%) |
Jul 9, 2026 15w ago | Institutional Cluster | $14.30 $14.56 | ▲ +1.82% | ▲ +1.39% | $12.02 (−15.94%) |
Jun 24, 2026 17w ago | Insider Cluster | $12.17 $12.70 | ▼ −4.36% | ▼ −5.08% | $12.02 (+1.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers